Digital therapeutics (DTx) represent a new generation of healthcare that uses innovative, clinically-validated disease management and direct treatment applications to enhance, and in some cases replace, current medical practices and treatments.
DTx products demonstrate safety and efficacy in randomized clinical trials, receive regulatory clearance when used as a medical device, integrate into clinical practice, may be prescribed by healthcare providers, and tailor to patients’ clinical needs, goals, and lifestyles.
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association with the mission of broadening the understanding, adoption, and integration of clinically-validated digital therapeutics into healthcare through education, advocacy, and research.
The Alliance provides a platform for leading DTx companies to engage with patients, healthcare providers, payers, academic institutions, technology organizations, and pharmaceutical manufacturers.
DTA members collaborate to enhance patient outcomes through assessing the value and impact of DTx solutions in clinical practice, constructing industry and regulatory frameworks, and encouraging data-driven integration and utilization of DTx solutions across the healthcare industry.